Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer
暂无分享,去创建一个
N. Stoecklein | O. Schmidt-Kittler | C. Klein | G. Riethmüller | Christoph A Klein | B. Polzer | Oleg Schmidt-Kittler | Bernhard Polzer | Gert Riethmüller | Thomas JF Blankenstein | Marco Petronio | Nikolas H Stoecklein | T. Blankenstein | Marco Petronio
[1] M W Kattan,et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] M. Speicher,et al. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[3] K. Aldape,et al. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[4] C. Klein. The biology and analysis of single disseminated tumour cells. , 2000, Trends in cell biology.
[5] D. Pinkel,et al. Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .
[6] R. Rosenberg,et al. Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis , 2000, British Journal of Cancer.
[7] G. Schlimok,et al. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients , 1992, The Lancet.
[8] G. Schlimok,et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[9] N. Maitland,et al. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. , 1998, Cancer research.
[10] M. Teixeira,et al. Cytogenetic polyclonality in tumors of the breast. , 1997, Cancer genetics and cytogenetics.
[11] H Sommer,et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Loeb. A Mutator Phenotype in Cancer 1 , 2001 .
[13] E Gabrielson,et al. Genetic divergence in the clonal evolution of breast cancer. , 1996, Cancer research.
[14] G. Bonadonna,et al. Adjuvant and neoadjuvant treatment of breast cancer. , 2001, Seminars in oncology.
[15] A. Andrén-sandberg,et al. Cytogenetic analysis of pancreatic carcinomas: Intratumor heterogeneity and nonrandom pattern of chromosome aberrations , 1998, Genes, chromosomes & cancer.
[16] A. Niendorf,et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. , 1997, The New England journal of medicine.
[17] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[18] F. Mitelman,et al. Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients , 1998, Genes, chromosomes & cancer.
[19] D. Smith,et al. Adjuvant and neoadjuvant therapy in prostate cancer. , 2001, Seminars in oncology.
[20] K. Pantel,et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases , 1996, The Lancet.
[21] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[22] Ahmedin Jemal,et al. Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden , 2002, Cancer.
[23] G. Schlimok,et al. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. , 2001, The Journal of urology.
[24] Peter A. Jones,et al. The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.
[25] J. Izbicki,et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] T. Dimpfl,et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.
[27] R. Cote,et al. Detection and clinical importance of micrometastatic disease. , 1999, Journal of the National Cancer Institute.
[28] K. Pantel,et al. Prognostic significance of bone marrow micrometastases in patients with gastric cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Macdonald. Adjuvant therapy for colon cancer , 1997 .
[30] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[31] H M Rosenberg,et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. , 2001, Journal of the National Cancer Institute.
[32] P. Roy-Burman,et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. , 1995, The American journal of pathology.
[33] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.